A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

Conditions

• Asthma

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Depemokimab — DRUG
  Depemokimab will be administered
• Placebo — DRUG
  Placebo will be administered

Study Details

The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).

Key Dates

First listed

Mar 6, 2026

Start date

Mar 13, 2026

Status verified

Aug 2026

Primary completion

Sep 23, 2030

Completion

Sep 23, 2030

Study Design

Enrollment

456 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Depemokimab
  Participants will be administered depemokimab along with standard of care (SoC).
• Placebo Comparator: Placebo
  Participants will be administered placebo along with SoC

Primary Outcome Measure

Annualized rate of clinically significant exacerbations [ Time Frame: Up to Week 156 ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (16)

Find similar trials in Little Rock, AR

Related Studies

• Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
  Recruiting · Gelb, Arthur F., M.D. · Lakewood, California
• Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
  PHASE4 · Recruiting · Gelb, Arthur F., M.D. · Lakewood, California
• Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma
  Recruiting · University of Oklahoma · Oklahoma City, Oklahoma
• Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
  PHASE2 · Recruiting · National Jewish Health · Denver, Colorado